10-Q Filing

CENCORA, INC. CIK: 1140859 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001140859-20-000022`
Period End Date	20200331
Filing Date	20200507
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	a10-qxq22020_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 86 Cash Flow Statement 77 Stockholders Equity 48 Comprehensive Income 28

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowances for returns and doubtful accounts	`AllowancesForReturnsAndDoubtfulAccounts`	$1.39B	USD	Point-in-time
Allowances for returns and doubtful accounts	`AllowancesForReturnsAndDoubtfulAccounts`	$1.22B	USD	Point-in-time
Common stock, par value (usd per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (usd per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.88B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	600.00M	shares	Point-in-time
Cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.49B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	600.00M	shares	Point-in-time
Cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.37B	USD	Point-in-time
Cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.69B	USD	Point-in-time
Common stock, issued (shares)	`CommonStockSharesIssued`	285.30M	shares	Point-in-time
Accounts receivable, less allowances for returns and doubtful accounts: $1,389,812 as of March 31, 2020 and $1,222,906 as of September 30, 2019	`AccountsReceivableNetCurrent`	$12.39B	USD	Point-in-time
Accounts receivable, less allowances for returns and doubtful accounts: $1,389,812 as of March 31, 2020 and $1,222,906 as of September 30, 2019	`AccountsReceivableNetCurrent`	$14.21B	USD	Point-in-time
Common stock, issued (shares)	`CommonStockSharesIssued`	286.75M	shares	Point-in-time
Common stock, outstanding (shares)	`CommonStockSharesOutstanding`	203.35M	shares	Point-in-time
Common stock, outstanding (shares)	`CommonStockSharesOutstanding`	206.76M	shares	Point-in-time
Inventories	`InventoryNet`	$11.10B	USD	Point-in-time
Inventories	`InventoryNet`	$11.06B	USD	Point-in-time
Treasury stock (shares)	`TreasuryStockShares`	83.40M	shares	Point-in-time
Right to recover asset	`ContractWithCustomerAssetGrossCurrent`	$1.15B	USD	Point-in-time
Treasury stock (shares)	`TreasuryStockShares`	78.53M	shares	Point-in-time
Right to recover asset	`ContractWithCustomerAssetGrossCurrent`	$1.30B	USD	Point-in-time
Income tax receivable (Note 4)	`IncomeTaxesReceivable`	$5.86M	USD	Point-in-time
Income tax receivable (Note 4)	`IncomeTaxesReceivable`	$699.49M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$157.38M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$175.37M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$31.18B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$28.13B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.77B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.42B	USD	Point-in-time
Goodwill	`Goodwill`	$6.71B	USD	Point-in-time
Goodwill	`Goodwill`	$6.70B	USD	Point-in-time
Other intangible assets	`IntangibleAssetsNetExcludingGoodwill`	$2.29B	USD	Point-in-time
Other intangible assets	`IntangibleAssetsNetExcludingGoodwill`	$1.94B	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$800.26M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$269.07M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$42.04B	USD	Point-in-time
TOTAL ASSETS	`Assets`	$39.17B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$30.72B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$28.39B	USD	Point-in-time
Accrued expenses and other	`AccruedLiabilitiesCurrent`	$869.00M	USD	Point-in-time
Accrued expenses and other	`AccruedLiabilitiesCurrent`	$1.06B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$522.81M	USD	Point-in-time
Short-term debt	`DebtCurrent`	$139.01M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$32.11B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$29.58B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$3.62B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$4.03B	USD	Point-in-time
Long-term financing obligation (Note 1)	`FinanceObligation`	$320.52M	USD	Point-in-time
Long-term financing obligation (Note 1)	`FinanceObligation`	-	USD	Point-in-time
Accrued income taxes	`AccruedIncomeTaxesNoncurrent`	$279.40M	USD	Point-in-time
Accrued income taxes	`AccruedIncomeTaxesNoncurrent`	$284.07M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.86B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.84B	USD	Point-in-time
Other liabilities	`OtherLiabilitiesNoncurrent`	$98.81M	USD	Point-in-time
Other liabilities	`OtherLiabilitiesNoncurrent`	$479.66M	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.01 par value - authorized, issued, and outstanding: 600,000,000 shares, 286,754,370 shares, and 203,351,729 shares as of March 31, 2020, respectively, and 600,000,000 shares, 285,295,170 shares, and 206,760,654 shares as of September 30, 2019, respectively	`CommonStockValue`	$2.85M	USD	Point-in-time
Common stock, $0.01 par value - authorized, issued, and outstanding: 600,000,000 shares, 286,754,370 shares, and 203,351,729 shares as of March 31, 2020, respectively, and 600,000,000 shares, 285,295,170 shares, and 206,760,654 shares as of September 30, 2019, respectively	`CommonStockValue`	$2.87M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$4.97B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$4.85B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$4.24B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$5.25B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-111.97M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-132.81M	USD	Point-in-time
Treasury stock, at cost: 83,402,641 shares as of March 31, 2020 and 78,534,516 shares as of September 30, 2019	`TreasuryStockValue`	$6.10B	USD	Point-in-time
Treasury stock, at cost: 83,402,641 shares as of March 31, 2020 and 78,534,516 shares as of September 30, 2019	`TreasuryStockValue`	$6.50B	USD	Point-in-time
Total AmerisourceBergen Corporation stockholders' equity	`StockholdersEquity`	$2.88B	USD	Point-in-time
Total AmerisourceBergen Corporation stockholders' equity	`StockholdersEquity`	$3.59B	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$114.52M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$114.29M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.07B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.04B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.05B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.16B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.99B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.71B	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$42.04B	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$39.17B	USD	Point-in-time

Income Statement 86 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	$43.32B	USD	1 Quarter
Revenue	`Revenues`	$88.71B	USD	2 Qtrs
Revenue	`Revenues`	$47.42B	USD	1 Quarter
Revenue	`Revenues`	$95.28B	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsAndServicesSold`	$85.99B	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsAndServicesSold`	$46.03B	USD	1 Quarter
Cost of goods sold	`CostOfGoodsAndServicesSold`	$92.66B	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsAndServicesSold`	$41.89B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.39B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.62B	USD	2 Qtrs
Gross profit	`GrossProfit`	$1.42B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.72B	USD	2 Qtrs
Distribution, selling, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.38B	USD	2 Qtrs
Distribution, selling, and administrative	`SellingGeneralAndAdministrativeExpense`	$628.04M	USD	1 Quarter
Distribution, selling, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.28B	USD	2 Qtrs
Distribution, selling, and administrative	`SellingGeneralAndAdministrativeExpense`	$693.41M	USD	1 Quarter
Depreciation	`DepreciationNonproduction`	$150.58M	USD	2 Qtrs
Depreciation	`DepreciationNonproduction`	$69.80M	USD	1 Quarter
Depreciation	`DepreciationNonproduction`	$75.22M	USD	1 Quarter
Depreciation	`DepreciationNonproduction`	$139.04M	USD	2 Qtrs
Amortization	`AmortizationOfIntangibleAssets`	$59.27M	USD	2 Qtrs
Amortization	`AmortizationOfIntangibleAssets`	$95.69M	USD	2 Qtrs
Amortization	`AmortizationOfIntangibleAssets`	$24.00M	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$48.55M	USD	1 Quarter
Employee severance, litigation, and other	`RestructuringCharges`	$67.73M	USD	1 Quarter
Employee severance, litigation, and other	`RestructuringCharges`	$107.04M	USD	2 Qtrs
Employee severance, litigation, and other	`RestructuringCharges`	$55.39M	USD	1 Quarter
Employee severance, litigation, and other	`RestructuringCharges`	$96.06M	USD	2 Qtrs
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$570.00M	USD	2 Qtrs
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$570.00M	USD	1 Quarter
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$223.65M	USD	1 Quarter
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$361.65M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$572.95M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$47.56M	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$525.39M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$309.51M	USD	1 Quarter
Other (income) loss	`NonoperatingIncomeExpense`	$-1.73M	USD	2 Qtrs
Other (income) loss	`NonoperatingIncomeExpense`	$14.49M	USD	1 Quarter
Other (income) loss	`NonoperatingIncomeExpense`	$11.40M	USD	2 Qtrs
Other (income) loss	`NonoperatingIncomeExpense`	$1.11M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-34.42M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-43.27M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-85.44M	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-65.43M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$505.79M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$18.78M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$276.20M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$451.34M	USD	2 Qtrs
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-651.89M	USD	2 Qtrs
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$31.51M	USD	2 Qtrs
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-694.91M	USD	1 Quarter
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-9.29M	USD	1 Quarter
Net income	`ProfitLoss`	$419.83M	USD	2 Qtrs
Net income	`ProfitLoss`	$971.11M	USD	1 Quarter
Net income	`ProfitLoss`	$28.07M	USD	1 Quarter
Net income	`ProfitLoss`	$1.16B	USD	2 Qtrs
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-961.00K	USD	2 Qtrs
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$938.00K	USD	1 Quarter
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$10.83M	USD	1 Quarter
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$9.76M	USD	2 Qtrs
Net income attributable to AmerisourceBergen Corporation	`NetIncomeLoss`	$27.14M	USD	1 Quarter
Net income attributable to AmerisourceBergen Corporation	`NetIncomeLoss`	$420.79M	USD	2 Qtrs
Net income attributable to AmerisourceBergen Corporation	`NetIncomeLoss`	$960.28M	USD	1 Quarter
Net income attributable to AmerisourceBergen Corporation	`NetIncomeLoss`	$1.15B	USD	2 Qtrs
Basic (usd per share)	`EarningsPerShareBasic`	$1.99	USD	2 Qtrs
Basic (usd per share)	`EarningsPerShareBasic`	$0.13	USD	1 Quarter
Basic (usd per share)	`EarningsPerShareBasic`	$5.58	USD	2 Qtrs
Basic (usd per share)	`EarningsPerShareBasic`	$4.68	USD	1 Quarter
Diluted (usd per share)	`EarningsPerShareDiluted`	$4.64	USD	1 Quarter
Diluted (usd per share)	`EarningsPerShareDiluted`	$0.13	USD	1 Quarter
Diluted (usd per share)	`EarningsPerShareDiluted`	$1.97	USD	2 Qtrs
Diluted (usd per share)	`EarningsPerShareDiluted`	$5.54	USD	2 Qtrs
Basic (shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	205.69M	shares	2 Qtrs
Basic (shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	211.50M	shares	2 Qtrs
Basic (shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	210.93M	shares	1 Quarter
Basic (shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	205.37M	shares	1 Quarter
Diluted (shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	207.29M	shares	2 Qtrs
Diluted (shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	213.28M	shares	2 Qtrs
Diluted (shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	212.56M	shares	1 Quarter
Diluted (shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	207.06M	shares	1 Quarter
Cash dividends declared per share of common stock (usd per share)	`CommonStockDividendsPerShareDeclared`	$0.40	USD	1 Quarter
Cash dividends declared per share of common stock (usd per share)	`CommonStockDividendsPerShareDeclared`	$0.40	USD	1 Quarter
Cash dividends declared per share of common stock (usd per share)	`CommonStockDividendsPerShareDeclared`	$0.42	USD	Point-in-time
Cash dividends declared per share of common stock (usd per share)	`CommonStockDividendsPerShareDeclared`	$0.80	USD	2 Qtrs
Cash dividends declared per share of common stock (usd per share)	`CommonStockDividendsPerShareDeclared`	$0.82	USD	2 Qtrs
Cash dividends declared per share of common stock (usd per share)	`CommonStockDividendsPerShareDeclared`	$0.42	USD	1 Quarter

Cash Flow Statement 77 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$419.83M	USD	2 Qtrs
Net income	`ProfitLoss`	$971.11M	USD	1 Quarter
Net income	`ProfitLoss`	$28.07M	USD	1 Quarter
Net income	`ProfitLoss`	$1.16B	USD	2 Qtrs
Depreciation, including amounts charged to cost of goods sold	`Depreciation`	$143.60M	USD	2 Qtrs
Depreciation, including amounts charged to cost of goods sold	`Depreciation`	$171.79M	USD	2 Qtrs
Amortization, including amounts charged to interest expense	`AdjustmentForAmortization`	$100.04M	USD	2 Qtrs
Amortization, including amounts charged to interest expense	`AdjustmentForAmortization`	$66.56M	USD	2 Qtrs
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$10.89M	USD	2 Qtrs
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$22.14M	USD	2 Qtrs
(Benefit) provision for deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-21.57M	USD	2 Qtrs
(Benefit) provision for deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$24.95M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$37.87M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$45.76M	USD	2 Qtrs
LIFO expense (credit)	`InventoryLIFOReservePeriodCharge`	$37.13M	USD	2 Qtrs
LIFO expense (credit)	`InventoryLIFOReservePeriodCharge`	$-69.83M	USD	2 Qtrs
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$570.00M	USD	2 Qtrs
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$570.00M	USD	1 Quarter
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$223.65M	USD	1 Quarter
Impairment of PharMEDium assets	`AssetImpairmentCharges`	$361.65M	USD	2 Qtrs
Gain on sale of an equity investment	`EquityMethodInvestmentRealizedGainLossOnDisposal`	$13.69M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$11.31M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$11.61M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$2.05B	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$880.80M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$152.36M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$420.19M	USD	2 Qtrs
Income tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$693.63M	USD	2 Qtrs
Income tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$-522.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$17.44M	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-1.58M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.35B	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.40B	USD	2 Qtrs
Accrued expenses, accrued income taxes, and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-169.72M	USD	2 Qtrs
Accrued expenses, accrued income taxes, and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-305.17M	USD	2 Qtrs
NET CASH PROVIDED BY OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$1.10B	USD	2 Qtrs
NET CASH PROVIDED BY OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$995.71M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$144.38M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$161.49M	USD	2 Qtrs
Cost of acquired companies, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$52.40M	USD	2 Qtrs
Cost of acquired companies, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Cost of equity investments	`PaymentstoAcquireEquitySecuritiesFVNI`	-	USD	2 Qtrs
Cost of equity investments	`PaymentstoAcquireEquitySecuritiesFVNI`	$30.58M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-7.16M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-2.66M	USD	2 Qtrs
NET CASH USED IN INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-211.23M	USD	2 Qtrs
NET CASH USED IN INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-167.80M	USD	2 Qtrs
Senior notes and other loan borrowings	`ProceedsFromIssuanceOfDebt`	$439.18M	USD	2 Qtrs
Senior notes and other loan borrowings	`ProceedsFromIssuanceOfDebt`	$46.40M	USD	2 Qtrs
Senior notes and other loan repayments	`RepaymentsOfDebt`	$46.15M	USD	2 Qtrs
Senior notes and other loan repayments	`RepaymentsOfDebt`	$456.59M	USD	2 Qtrs
Borrowings under revolving and securitization credit facilities	`ProceedsFromLinesOfCredit`	$87.95M	USD	2 Qtrs
Borrowings under revolving and securitization credit facilities	`ProceedsFromLinesOfCredit`	$541.07M	USD	2 Qtrs
Repayments under revolving and securitization credit facilities	`RepaymentsOfLinesOfCredit`	$539.67M	USD	2 Qtrs
Repayments under revolving and securitization credit facilities	`RepaymentsOfLinesOfCredit`	$87.26M	USD	2 Qtrs
Purchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$407.15M	USD	2 Qtrs
Purchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$347.96M	USD	2 Qtrs
Exercises of stock options	`ProceedsFromStockOptionsExercised`	$37.59M	USD	2 Qtrs
Exercises of stock options	`ProceedsFromStockOptionsExercised`	$76.76M	USD	2 Qtrs
Cash dividends on common stock	`PaymentsOfDividendsCommonStock`	$170.43M	USD	2 Qtrs
Cash dividends on common stock	`PaymentsOfDividendsCommonStock`	$170.54M	USD	2 Qtrs
Tax withholdings related to restricted share vesting	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$5.67M	USD	2 Qtrs
Tax withholdings related to restricted share vesting	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$9.59M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-589.00K	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-6.39M	USD	2 Qtrs
NET CASH USED IN FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$-510.16M	USD	2 Qtrs
NET CASH USED IN FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$-508.87M	USD	2 Qtrs
INCREASE IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$383.23M	USD	2 Qtrs
INCREASE IN CASH AND CASH EQUIVALENTS	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$317.74M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.88B	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.49B	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.37B	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.69B	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.88B	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.49B	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.37B	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.69B	USD	Point-in-time

Stockholders Equity 48 line items

Line Item	Tag	Value	Unit	Period
Cash dividends (in dollars per share)	`CommonStockDividendsPerShareCashPaid`	$0.82	USD	1 Quarter
Cash dividends (in dollars per share)	`CommonStockDividendsPerShareCashPaid`	$0.40	USD	2 Qtrs
Cash dividends (in dollars per share)	`CommonStockDividendsPerShareCashPaid`	$0.40	USD	1 Quarter
Cash dividends (in dollars per share)	`CommonStockDividendsPerShareCashPaid`	$0.80	USD	2 Qtrs
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.07B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.04B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.05B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.16B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.99B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.71B	USD	Point-in-time
Net income (loss)	`ProfitLoss`	$419.83M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$971.11M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$28.07M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$1.16B	USD	2 Qtrs
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-30.37M	USD	2 Qtrs
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-3.85M	USD	2 Qtrs
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$7.64M	USD	1 Quarter
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-55.84M	USD	1 Quarter
Cash dividends	`DividendsCommonStockCash`	$170.54M	USD	2 Qtrs
Cash dividends	`DividendsCommonStockCash`	$84.89M	USD	1 Quarter
Cash dividends	`DividendsCommonStockCash`	$87.45M	USD	1 Quarter
Cash dividends	`DividendsCommonStockCash`	$170.43M	USD	2 Qtrs
Exercises of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$56.64M	USD	1 Quarter
Exercises of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$15.19M	USD	1 Quarter
Exercises of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$37.59M	USD	2 Qtrs
Exercises of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$76.76M	USD	2 Qtrs
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$45.76M	USD	2 Qtrs
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$14.39M	USD	1 Quarter
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$37.87M	USD	2 Qtrs
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$6.10M	USD	1 Quarter
Purchases of common stock	`TreasuryStockValueAcquiredCostMethod`	$98.12M	USD	1 Quarter
Purchases of common stock	`TreasuryStockValueAcquiredCostMethod`	$262.62M	USD	1 Quarter
Purchases of common stock	`TreasuryStockValueAcquiredCostMethod`	$392.39M	USD	2 Qtrs
Purchases of common stock	`TreasuryStockValueAcquiredCostMethod`	$323.97M	USD	2 Qtrs
Employee tax withholdings related to restricted share vesting	`EmployeeTaxWithholdingsRelatedToRestrictedShareVesting`	$13.00K	USD	1 Quarter
Employee tax withholdings related to restricted share vesting	`EmployeeTaxWithholdingsRelatedToRestrictedShareVesting`	$5.67M	USD	2 Qtrs
Employee tax withholdings related to restricted share vesting	`EmployeeTaxWithholdingsRelatedToRestrictedShareVesting`	$-11.00K	USD	1 Quarter
Employee tax withholdings related to restricted share vesting	`EmployeeTaxWithholdingsRelatedToRestrictedShareVesting`	$9.59M	USD	2 Qtrs
Other	`ShareholdersEquityOther`	$-538.00K	USD	2 Qtrs
Other	`ShareholdersEquityOther`	$-207.00K	USD	1 Quarter
Other	`ShareholdersEquityOther`	$-415.00K	USD	2 Qtrs
Other	`ShareholdersEquityOther`	$-375.00K	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.07B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.04B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.05B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.16B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.99B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.71B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$419.83M	USD	2 Qtrs
Net income	`ProfitLoss`	$971.11M	USD	1 Quarter
Net income	`ProfitLoss`	$28.07M	USD	1 Quarter
Net income	`ProfitLoss`	$1.16B	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-55.86M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$7.41M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-3.96M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-30.41M	USD	2 Qtrs
Other	`OtherComprehensiveIncomeOtherNetOfTax`	$15.00K	USD	1 Quarter
Other	`OtherComprehensiveIncomeOtherNetOfTax`	$113.00K	USD	2 Qtrs
Other	`OtherComprehensiveIncomeOtherNetOfTax`	$34.00K	USD	2 Qtrs
Other	`OtherComprehensiveIncomeOtherNetOfTax`	$225.00K	USD	1 Quarter
Total other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-30.37M	USD	2 Qtrs
Total other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-3.85M	USD	2 Qtrs
Total other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$7.64M	USD	1 Quarter
Total other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-55.84M	USD	1 Quarter
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$1.13B	USD	2 Qtrs
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$915.27M	USD	1 Quarter
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$35.71M	USD	1 Quarter
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$415.98M	USD	2 Qtrs
Comprehensive income attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$1.08M	USD	2 Qtrs
Comprehensive income attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$68.00K	USD	1 Quarter
Comprehensive income attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$234.00K	USD	2 Qtrs
Comprehensive income attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$836.00K	USD	1 Quarter
Comprehensive income attributable to AmerisourceBergen Corporation	`ComprehensiveIncomeNetOfTax`	$34.88M	USD	1 Quarter
Comprehensive income attributable to AmerisourceBergen Corporation	`ComprehensiveIncomeNetOfTax`	$915.20M	USD	1 Quarter
Comprehensive income attributable to AmerisourceBergen Corporation	`ComprehensiveIncomeNetOfTax`	$414.90M	USD	2 Qtrs
Comprehensive income attributable to AmerisourceBergen Corporation	`ComprehensiveIncomeNetOfTax`	$1.13B	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.